Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis

• Published in: Frontiers in endocrinology (Lausanne) 2023-11, Vol.14, p.1295865
• Main Authors: Galligan, Anna, Iravani, Amir, Lasocki, Arian, Wallace, Roslyn, Weppler, Alison M, Sachithanandan, Nirupa, Chiang, Cherie, Colman, Peter G, Wentworth, John, Spain, Lavinia, Au-Yeung, George, Lee, Belinda, Kay, Thomas W H, Hicks, Rodney J, Sandhu, Shahneen, Krishnamurthy, Balasubramanian
• Format: Article
• Language: English
• Subjects: cancer imaging; combination immune checkpoint inhibition; Endocrinology; Female; Fluorodeoxyglucose F18; Humans; hypophysitis; Hypophysitis - diagnostic imaging; Hypophysitis - drug therapy; Immune Checkpoint Inhibitors - therapeutic use; immune related adverse events; immunotherapy; Male; Middle Aged; Neoplasms; Pituitary Diseases; pituitary gland; Positron Emission Tomography Computed Tomography - methods; Retrospective Studies
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2023.1295865

Hypophysitis is reported in 8.5%-14% of patients receiving combination immune checkpoint inhibition (cICI) but can be a diagnostic challenge. This study aimed to assess the role of routine diagnostic imaging performed during therapeutic monitoring of combination anti-CTLA-4/anti-PD-1 treatment in the identification of hypophysitis and the relationship of imaging findings to clinical diagnostic criteria. This retrospective cohort study identified patients treated with cICI between January 2016 and January 2019 at a quaternary melanoma service. Medical records were reviewed to identify patients with a documented diagnosis of hypophysitis based on clinical criteria. Available structural brain imaging with magnetic resonance imaging (MRI) or computed tomography (CT) of the brain and 2-deoxy-2-[ F]fluoro-D-glucose positron emission tomography with computed tomography (FDG-PET/CT) were assessed retrospectively. The main radiological outcome measures were a relative change in pituitary size or FDG uptake temporally attributed to cICI. There were 162 patients (median age 60 years, 30% female) included. A total of 100 and 134 had serial CT/MRI of the brain and FDG-PET/CT, respectively. There were 31 patients who had a documented diagnosis of hypophysitis and an additional 20 who had isolated pituitary imaging findings. The pituitary gland enlargement was mild, and the largest absolute gland size was 13 mm, with a relative increase of 7 mm from baseline. There were no cases of optic chiasm compression. Pituitary enlargement and increased FDG uptake were universally transient. High-dose glucocorticoid treatment for concurrent irAEs prevented assessment of the pituitary-adrenal axis in 90% of patients with isolated imaging findings. Careful review of changes in pituitary characteristics on imaging performed for assessment of therapeutic response to iICI may lead to increased identification and more prompt management of cICI-induced hypophysitis.